Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel
Arch Therapeutics partners with Centurion Therapeutics. (Credit: 12019/Pixabay)
Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced it has entered into a distribution agreement with Centurion Therapeutics Inc. (“Centurion”), an exclusive strategic partner to the world’s largest tissue bank, to expand sales opportunities for AC5® Advanced Wound System.
Centurion distributes a comprehensive portfolio of aseptically processed human tissues to support surgeons in a broad array of specialties through over a hundred contracted wound care distributors nationwide. AC5 Advanced Wound System will be added to their advanced wound care product line as part of this distribution agreement.
“Centurion is a progressive and well-established leader within the hospital-based advanced wound care market. Partnering with Centurion supports our strategic plan to expand AC5 Advanced Wound System into non-government U.S.-based hospitals. The agreement complements our current focus of selling to government hospitals across the country and expands our sales footprint within key selling channels,” stated Dan Yrigoyen, Vice President of Sales for Arch Therapeutics.
Robert Goodwin, President and CEO of Centurion Therapeutics added, “Centurion’s partnership with Arch offers compelling strategic advantages and significant growth opportunities for both companies. Our network boasts a strong track-record of success, which affords us the opportunity to be very selective in choosing partners. My team and I are extremely impressed with the technology behind AC5 Advanced Wound System, and we are enthusiastic to work with Arch to help grow and drive its utilization in hospitals and operating rooms across the country.”
AC5 Advanced Wound System is indicated for the management of partial and full-thickness wounds, such as pressure sores, venous leg ulcers, diabetic foot ulcers, and surgical wounds and received marketing authorization by the US Food and Drug Administration. Early data demonstrating the effects of its proprietary self-assembling peptides in challenging wounds has been positive and presented by key opinion leaders in peer-reviewed publications and at recent wound care conferences.
“We remain committed to providing improved outcomes for patients with acute and chronic wounds, and the partnership with Centurion is an exciting and important development in support of our overall commercialization plan,” concluded Yrigoyen.
Source: Company Press Release